vs
Side-by-side financial comparison of RB GLOBAL INC. (RBA) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.3B vs $1.2B, roughly 1.8× RB GLOBAL INC.). Zoetis runs the higher net margin — 26.6% vs 11.0%, a 15.6% gap on every dollar of revenue. On growth, RB GLOBAL INC. posted the faster year-over-year revenue change (11.4% vs 2.9%). Over the past eight quarters, RB GLOBAL INC.'s revenue compounded faster (6.1% CAGR vs -2.1%).
Ritchie Bros. Auctioneers (RBA), or simply Ritchie Bros., is a publicly traded company legally domiciled in Canada with headquarters in Westchester, Illinois. Its common shares are traded on the Toronto Stock Exchange and the New York Stock Exchange.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
RBA vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.3B |
| Net Profit | $135.6M | $601.0M |
| Gross Margin | — | 71.7% |
| Operating Margin | 17.6% | — |
| Net Margin | 11.0% | 26.6% |
| Revenue YoY | 11.4% | 2.9% |
| Net Profit YoY | 19.7% | -0.2% |
| EPS (diluted) | $0.66 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | $2.3B | ||
| Q4 25 | $1.2B | $2.4B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.1B | $2.2B | ||
| Q4 24 | $1.1B | $2.3B | ||
| Q3 24 | $981.8M | $2.4B | ||
| Q2 24 | $1.1B | $2.4B |
| Q1 26 | $135.6M | $601.0M | ||
| Q4 25 | $109.7M | $603.0M | ||
| Q3 25 | $95.5M | $721.0M | ||
| Q2 25 | $109.8M | $718.0M | ||
| Q1 25 | $113.4M | $631.0M | ||
| Q4 24 | $118.5M | $581.0M | ||
| Q3 24 | $76.1M | $682.0M | ||
| Q2 24 | $111.1M | $624.0M |
| Q1 26 | — | 71.7% | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | 17.6% | — | ||
| Q4 25 | 14.7% | 31.9% | ||
| Q3 25 | 14.5% | 37.0% | ||
| Q2 25 | 15.9% | 36.7% | ||
| Q1 25 | 17.1% | 36.5% | ||
| Q4 24 | 18.1% | 31.6% | ||
| Q3 24 | 15.6% | 36.6% | ||
| Q2 24 | 18.4% | 33.0% |
| Q1 26 | 11.0% | 26.6% | ||
| Q4 25 | 9.1% | 25.3% | ||
| Q3 25 | 8.7% | 30.0% | ||
| Q2 25 | 9.3% | 29.2% | ||
| Q1 25 | 10.2% | 28.4% | ||
| Q4 24 | 10.4% | 25.1% | ||
| Q3 24 | 7.8% | 28.6% | ||
| Q2 24 | 10.1% | 26.4% |
| Q1 26 | $0.66 | $1.42 | ||
| Q4 25 | $0.53 | $1.37 | ||
| Q3 25 | $0.43 | $1.63 | ||
| Q2 25 | $0.53 | $1.61 | ||
| Q1 25 | $0.55 | $1.41 | ||
| Q4 24 | $0.58 | $1.29 | ||
| Q3 24 | $0.36 | $1.50 | ||
| Q2 24 | $0.54 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $667.2M | — |
| Total DebtLower is stronger | $2.6B | — |
| Stockholders' EquityBook value | $5.6B | — |
| Total Assets | $12.4B | — |
| Debt / EquityLower = less leverage | 0.45× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $667.2M | — | ||
| Q4 25 | $531.5M | — | ||
| Q3 25 | $674.7M | $2.1B | ||
| Q2 25 | $710.2M | $1.4B | ||
| Q1 25 | $578.1M | $1.7B | ||
| Q4 24 | $533.9M | $2.0B | ||
| Q3 24 | $650.7M | $1.7B | ||
| Q2 24 | $599.5M | $1.6B |
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.8B | — |
| Q1 26 | $5.6B | — | ||
| Q4 25 | $5.6B | $3.3B | ||
| Q3 25 | $5.5B | $5.4B | ||
| Q2 25 | $5.5B | $5.0B | ||
| Q1 25 | $5.3B | $4.7B | ||
| Q4 24 | $5.2B | $4.8B | ||
| Q3 24 | $5.2B | $5.2B | ||
| Q2 24 | $5.2B | $5.0B |
| Q1 26 | $12.4B | — | ||
| Q4 25 | $12.1B | $15.5B | ||
| Q3 25 | $12.2B | $15.2B | ||
| Q2 25 | $12.2B | $14.5B | ||
| Q1 25 | $11.9B | $14.1B | ||
| Q4 24 | $11.8B | $14.2B | ||
| Q3 24 | $11.9B | $14.4B | ||
| Q2 24 | $12.1B | $14.2B |
| Q1 26 | 0.45× | — | ||
| Q4 25 | 0.42× | — | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 0.52× | — | ||
| Q2 24 | 0.55× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $224.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.65× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $224.1M | — | ||
| Q4 25 | $255.2M | $893.0M | ||
| Q3 25 | $239.7M | $938.0M | ||
| Q2 25 | $326.5M | $486.0M | ||
| Q1 25 | $156.8M | $587.0M | ||
| Q4 24 | $184.5M | $905.0M | ||
| Q3 24 | $285.4M | $951.0M | ||
| Q2 24 | $337.3M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $186.5M | $732.0M | ||
| Q3 25 | $188.5M | $805.0M | ||
| Q2 25 | $241.7M | $308.0M | ||
| Q1 25 | $102.5M | $438.0M | ||
| Q4 24 | $127.9M | $689.0M | ||
| Q3 24 | $248.5M | $784.0M | ||
| Q2 24 | $308.6M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | 15.5% | 30.7% | ||
| Q3 25 | 17.3% | 33.5% | ||
| Q2 25 | 20.4% | 12.5% | ||
| Q1 25 | 9.2% | 19.7% | ||
| Q4 24 | 11.2% | 29.7% | ||
| Q3 24 | 25.3% | 32.8% | ||
| Q2 24 | 28.2% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | 6.7% | ||
| Q3 25 | 4.7% | 5.5% | ||
| Q2 25 | 7.2% | 7.2% | ||
| Q1 25 | 4.9% | 6.7% | ||
| Q4 24 | 5.0% | 9.3% | ||
| Q3 24 | 3.8% | 7.0% | ||
| Q2 24 | 2.6% | 5.6% |
| Q1 26 | 1.65× | — | ||
| Q4 25 | 2.33× | 1.48× | ||
| Q3 25 | 2.51× | 1.30× | ||
| Q2 25 | 2.97× | 0.68× | ||
| Q1 25 | 1.38× | 0.93× | ||
| Q4 24 | 1.56× | 1.56× | ||
| Q3 24 | 3.75× | 1.39× | ||
| Q2 24 | 3.04× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RBA
| Transactional buyer revenue | $577.5M | 47% |
| Inventory sales revenue | $336.9M | 27% |
| Transactional seller revenue | $241.3M | 20% |
| Marketplace services revenue | $78.9M | 6% |
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
